Cargando…

Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention

BACKGROUND: HPV test implementation as a primary screening tool has the potential to decrease cervical cancer incidence as shown by several studies around the world. However, in many low-resource settings, the HPV test introduction has been backed down mainly due to its price. In this study, we pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Surriabre, Pedro, Torrico, Andrea, Vargas, Tania, Ugarte, Fuantina, Rodriguez, Patricia, Fontaine, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794773/
https://www.ncbi.nlm.nih.gov/pubmed/31615443
http://dx.doi.org/10.1186/s12879-019-4527-9
_version_ 1783459358706761728
author Surriabre, Pedro
Torrico, Andrea
Vargas, Tania
Ugarte, Fuantina
Rodriguez, Patricia
Fontaine, Véronique
author_facet Surriabre, Pedro
Torrico, Andrea
Vargas, Tania
Ugarte, Fuantina
Rodriguez, Patricia
Fontaine, Véronique
author_sort Surriabre, Pedro
collection PubMed
description BACKGROUND: HPV test implementation as a primary screening tool has the potential to decrease cervical cancer incidence as shown by several studies around the world. However, in many low-resource settings, the HPV test introduction has been backed down mainly due to its price. In this study, we present a novel low-cost strategy involving simple devices and techniques for high-risk human papillomavirus (HR-HPV) detection. The analytical performance to detect HR-HPV infections of this novel strategy was assessed by comparing it with the Hybrid Capture 2 system (HC2), which is used as gold standard. METHODS: Paired-cervical samples were collected from 541 women assisting to gynecological services in an outpatient clinic. One sample was transported in the Hybrid Capture Standard Transport Medium for HR-HPV detection by the HC2. The second sample was transported on glass slide for detection by PCR-based techniques (GP-EIA, BSGP-EIA and pU 1 M-L/2R). RESULTS: The level of agreement between the PCR-based techniques and HC2 system was determined with the Cohen’s kappa value. The kappa values between HC2 and GP-EIA, BSGP-EIA and pU 1 M-L/2R were 0.71 (CI 95% 0.63–0.78), 0.78 (CI 95% 0.71–0.84) and 0.63 (CI 95% 0.55–0.72), respectively. However, when the results from both BSGP-EIA and pU 1 M-L/2R were combined, the level of agreement with HC2 was increased to 0.82 (CI 95% 0.76–0.88), reflecting a very good agreement between the two HR-HPV detection strategies. Furthermore, the sensitivity of both techniques combined was also increased compared to the BSGP-EIA (88.7% vs 77.4%) and the pU (88.7 vs 60.9%) without penalizing the specificity obtained with the BSGP-EIA (95.1% vs 96.9%) and the pU (95.1% vs 96.5%). CONCLUSIONS: This novel strategy, combining two PCR-based techniques for HR-HPV detection, could be useful for cervical cancer screening in self-collected samples in low-income countries.
format Online
Article
Text
id pubmed-6794773
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67947732019-10-21 Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention Surriabre, Pedro Torrico, Andrea Vargas, Tania Ugarte, Fuantina Rodriguez, Patricia Fontaine, Véronique BMC Infect Dis Research Article BACKGROUND: HPV test implementation as a primary screening tool has the potential to decrease cervical cancer incidence as shown by several studies around the world. However, in many low-resource settings, the HPV test introduction has been backed down mainly due to its price. In this study, we present a novel low-cost strategy involving simple devices and techniques for high-risk human papillomavirus (HR-HPV) detection. The analytical performance to detect HR-HPV infections of this novel strategy was assessed by comparing it with the Hybrid Capture 2 system (HC2), which is used as gold standard. METHODS: Paired-cervical samples were collected from 541 women assisting to gynecological services in an outpatient clinic. One sample was transported in the Hybrid Capture Standard Transport Medium for HR-HPV detection by the HC2. The second sample was transported on glass slide for detection by PCR-based techniques (GP-EIA, BSGP-EIA and pU 1 M-L/2R). RESULTS: The level of agreement between the PCR-based techniques and HC2 system was determined with the Cohen’s kappa value. The kappa values between HC2 and GP-EIA, BSGP-EIA and pU 1 M-L/2R were 0.71 (CI 95% 0.63–0.78), 0.78 (CI 95% 0.71–0.84) and 0.63 (CI 95% 0.55–0.72), respectively. However, when the results from both BSGP-EIA and pU 1 M-L/2R were combined, the level of agreement with HC2 was increased to 0.82 (CI 95% 0.76–0.88), reflecting a very good agreement between the two HR-HPV detection strategies. Furthermore, the sensitivity of both techniques combined was also increased compared to the BSGP-EIA (88.7% vs 77.4%) and the pU (88.7 vs 60.9%) without penalizing the specificity obtained with the BSGP-EIA (95.1% vs 96.9%) and the pU (95.1% vs 96.5%). CONCLUSIONS: This novel strategy, combining two PCR-based techniques for HR-HPV detection, could be useful for cervical cancer screening in self-collected samples in low-income countries. BioMed Central 2019-10-15 /pmc/articles/PMC6794773/ /pubmed/31615443 http://dx.doi.org/10.1186/s12879-019-4527-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Surriabre, Pedro
Torrico, Andrea
Vargas, Tania
Ugarte, Fuantina
Rodriguez, Patricia
Fontaine, Véronique
Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title_full Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title_fullStr Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title_full_unstemmed Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title_short Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
title_sort assessment of a new low-cost, pcr-based strategy for high-risk human papillomavirus dna detection for cervical cancer prevention
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794773/
https://www.ncbi.nlm.nih.gov/pubmed/31615443
http://dx.doi.org/10.1186/s12879-019-4527-9
work_keys_str_mv AT surriabrepedro assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention
AT torricoandrea assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention
AT vargastania assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention
AT ugartefuantina assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention
AT rodriguezpatricia assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention
AT fontaineveronique assessmentofanewlowcostpcrbasedstrategyforhighriskhumanpapillomavirusdnadetectionforcervicalcancerprevention